Healthcare Review: Boston Scientific Corporation (NYSE:BSX), Gilead Sciences, Inc. (NASDAQ:GILD)

Lakeway, NY -- (SBWIRE) -- 02/22/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Boston Scientific Corporation (NYSE:BSX) will participate in the Citi 2013 Global Healthcare Conference on February 25 in New York.

Jeff Capello, Executive Vice President and Chief Financial Officer, will participate in a 20-minute presentation followed by a 20-minute question and answer session regarding the company.

Will BSX continue To Maintain The Solid Momentum? Find Out Here

Interested users can view the live webcast of the presentation and question and answer session on the Investor Relations section of the Boston Scientific website at www.bostonscientific.com/investors. Viewers are advised to register 15 minutes before the scheduled time to ensure timely connection.

Citi is hosting the webcast and a replay will be archived and available at www.bostonscientific.com/investors after one hour following the completion of question and answer session.

Gilead Sciences, Inc. (NASDAQ:GILD)) recently presented data from a phase III study, which evaluated the performance of sofosbuvir combined with ribavirin in patients suffering from genotype 2 or 3 of the chronic hepatitis C virus. The study was conducted on patients who did not respond to prior therapies for the disease. As a part of the study, the patients were evaluated at 12 and 16-week courses of the candidate. Gilead aims to develop an all-oral treatment regimen to combat HCV.

Will GILD Move Back To New highs After The Recent retreat? Get Free Trend Analysis Here

Through the study, it was found out that Sofosbuvir is safe and well tolerated. None of the patients opted out of the study due to adverse effects.

Gilead Sciences is evaluating sofosbuvir in HCV patients in other phase III studies, which include Positron, Fission and Neutrino. Based on the data from the studies, Gilead intends to get regulatory approvals for the candidate in the US and EU in the second quarter of 2013.

Successful development of sofosbuvir will boost the company’s top line and strengthen its position in the lucrative HCV market. Out of the huge population suffering from HCV infection, very few patients get proper treatment. Thus, the field is open to new and better treatments for the HCV patients.

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
?